Loading stock data…
DHR
$188.41+4.88 (+2.66%)
Market ClosedLast close Jun 9
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Danaher Corporation in the Healthcare sector is trading at $188.41 with a market capitalization of $121.7B. Wall Street consensus targets $244.27 (22 analysts), implying a +29.6% move over the next 12 months. The stock is currently 22% below its 52-week high of $242.80, remaining 7.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 75 is overbought against a weak tape. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +29.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 75 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$188.41
Potential Upside
8.2%
Whystock Fair Value$203.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus22 analysts
Mean target$244.27+29.6%
Range$200.00 – $310.00
Fundamentals
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$121.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.33
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.72%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.97%
Volume
Today's trading volume
5.87M
Recent News
Wolfe Research Downgrades Danaher Corporation (DHR)
Danaher Corporation (NYSE:DHR) is one of the best healthcare stocks to buy with highest upside potential. Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is “a […]
Everpure Jumps 34% in a Year: Should Investors Bet on the Stock?
P gains 33.9% in a year, powered by surging subscriptions, high ROE, and upbeat 2027-2028 revenue and EPS estimates.
SIRI Stock Surges 5% After-Hours On S&P MidCap 400 Inclusion
The index provider said Sirius XM will take Masimo’s (MASI) slot in the benchmark effective prior to the market open on Thursday, June 11.
Why Wall Street Sees Danaher (DHR) Benefiting From Improving Industry Conditions
With 110 hedge fund holders as of Q1 2026, Danaher Corporation (NYSE:DHR) is among the Top 10 Stocks That Members of Congress Own. On May 26, Citi resumed coverage of Danaher Corporation (NYSE:DHR) with a Buy rating and a $230 price target following a prior suspension of coverage. The firm pointed to Danaher’s reaffirmation of its fiscal […]
Danaher Insiders Sold US$235m Of Shares Suggesting Hesitancy
Many Danaher Corporation ( NYSE:DHR ) insiders ditched their stock over the past year, which may be of interest to the...